Technologies

Diagnostic Assays

Diagnostic Assays Portfolios

Most Recent Inventions

Porous Silicon Nanomembranes for the Rapid Separation of Macromolecules by Size and Shape

Researchers at the University of Wisconsin-Platteville have developed a unique nanomembrane for the separation of biomolecules based on their three-dimensional geometries. These “macromolecular sieves” are produced from laser-etched silicon nanomembranes. The pores in these membranes have openings in the sub-micron range but are designed to significantly reduce the flow impedance of the filtered solution. This design feature allows for faster filtration time when compared with traditional membranes. Nanomembranes with square and rectangular geometries have been produced. Desirable characteristics of the square opening membrane include a high open area of 45% and low standard deviation in opening size (less than 5%). Additionally, the fabricated membranes have been tested with vacuum pumps and show no signs of damage after repeated filtrations with 15 psi of applied pressure differential. Currently, reducing opening size below 100 nm and introducing openings of varying geometries is under development. Further efforts are also underway to decrease the manufacture time and increase the overall scalability of the membrane patterning process.
T180038WO01

Enhanced Endotoxin Detection: New Advantages in Liquid Crystal Assays for Gram-Negative Pathogens

UW–Madison researchers have now demonstrated enhanced endotoxin detection in the presence of masking agents in their previous liquid crystal system.

Unlike the LAL assay, the LC-based method does not suffer from LER or any loss of sensitivity due to the presence of cations (e.g., Ca2+ or Mg2+), buffers (e.g., citrate), surfactants (e.g., SDS), chelating agents (e.g., EDTA), proteins or nucleic acids (e.g., DNA or RNA). Thus, the LC-based method provides faster and cheaper detection of endotoxin when compared to existing methods, such as the LAL assay.
P160072WO01

Predicting Glucoregulatory Dysfunction

UW–Madison researchers have developed a method based on blood lipid chemistry to identify a subject at risk for glucoregulatory dysfunction. The method involves obtaining a biosample from the subject, separating the diacylglycerol fatty acids and determining if the concentration is above or below a control range.
P150057US02

Blood Protein Biomarkers for Detection of Colon Cancer

UW–Madison researchers have developed methods and kits for diagnosing colon cancer, including precancerous and early stage disease, using protein biomarkers in blood/serum. Approximately 30 peptides identified and validated in animal models were used to conduct targeted proteomic analysis in humans. The serum levels of several of the biomarkers correlated with cancer incidence and outcomes in the study of normal patients versus those with stage 1, 2 or stage 3 colon cancer.
P150077US02

Eight Hybridoma Cell Lines Producing Monoclonal Antibodies Against La Crosse Encephalitis Virus

UW-Madison researchers have now produced eight lines of hybridomas, one of which is specific for G1, five of which are specific for G2, and two of which recognize both G1 and G2. Frozen stocks are available at UW-Madison.
P01150US

Most Recent Patents

Assay to Determine Risk of Fungal Infection

More specifically, the researchers have developed a detection agent made up of calnexin peptides that recognize the telltale signs of infection. The peptides are able to track how a patient’s helper T cells respond to infection and/or vaccination.
P140236US02

Noninvasive Assay for Bovine Embryo Quality

UW–Madison researchers have identified 11 microRNAs (miRNAs) and 18 mRNAs as indicators of healthy IVF embryo development. They discovered that the miRNAs are differentially expressed between bovine blastocyst-stage embryos and those that fail to develop (‘degenerates’). This is the first report that miRNA levels in the culture medium differ among embryos of different developmental fate and can be used as indicators of embryo viability.
P150131US02

Biomarkers for Detecting Prostate Cancer

UW–Madison researchers have identified eight genetic markers, or biomarkers, for prostate cancer. They can be detected in histologically normal prostate samples and/or the bodily fluids of men with no history of prostate cancer.

The biomarkers act as red flags, exhibiting abnormal methylation levels when cancer is present in peripheral prostate tissue (this is called cancer ‘field defect’). These changes are believed to represent early stages of the cancer process.

The biomarkers are associated with the genes CAV1, EVX1, MCF2L, FGF1, WNT2, NCR2, EXT1 and SPAG4.
P130258US03